VRX INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Securities Class Action Against Valeant Pharmaceuticals International, Inc.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to VRX INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Securities Class Action Against Valeant Pharmaceuticals International, Inc.

Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis Intact

November 6, 2015 6:29 AM EST

Guggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a Buy rating saying the investment thesis remains intact.

Chen commented, "We are lowering our PT for VRX to $195 from $300. The decrease in our PT is... More